n Cardiovascular Journal of Africa - Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial : drug trends in cardiology
|Article Title||Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial : drug trends in cardiology|
|© Publisher:||Clinics Cardive Publishing|
|Journal||Cardiovascular Journal of Africa|
|Publication Date||Aug 2013|
Results presented at the recent 2013 European Society of Cardiology congress in Amsterdam, The Netherlands, and published in the New England Journal of Medicine contribute to on-going questions concerning the safety of many diabetes treatments, particularly regarding the impact of their use on risk of cardiovascular death, heart attack or stroke. SAVOR (Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus) is the largest cardiovascular outcomes trial to study a diverse population of type 2 diabetes mellitus (T2DM) patients at high risk for cardiovascular events.
Article metrics loading...